An Epidemiological Registry Study to Evaluate Clinical Practice Treatment in Patients With Bipolar Disorder
REED
1 other identifier
observational
16,000
0 countries
N/A
Brief Summary
The aim of this study is to describe the treatment pattern and patient characteristics in real life setting in patients with Bipolar disorder treated with Seroquel XR and/or Seroquel IR in Sweden.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2011
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 17, 2011
CompletedFirst Posted
Study publicly available on registry
October 20, 2011
CompletedStudy Start
First participant enrolled
November 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2012
CompletedAugust 21, 2014
August 1, 2014
5 months
October 17, 2011
August 20, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Description of detailed clinical treatment in terms of duration of treatment, doses, drug switches, and add-on therapy, in patients with BD and on treatment with quetiapine XR and/or quetiapine IR before, at and after the index date.
1st of January 2009 to 31st of December 2010.
Secondary Outcomes (3)
Description of co-morbidity, demographics, sick leave, early retirement and socioeconomic factors in patients with BD and on treatment with quetiapine XR and/or quetiapine IR before and at the index date.
1st of January 2009 to 31st of December 2010.
Description of the detailed clinical treatment in terms of duration of treatment, doses, drug switches, and add-on therapy, in patients with BD, including all drug treatment after the index date
1st of January 2009 to 31st of December 2010.
Description of co-morbidity, demographics, sick leave, early retirement and socioeconomic factors in patients with BD, including all drug treatment before and at the index date
1st of January 2009 to 31st of December 2010.
Eligibility Criteria
All patients who have been hospitalised in Sweden at least once since 1987 with a diagnosis during hospitalisation of Bipolar Disorder.
You may qualify if:
- Patients with a diagnosis of BD.
You may not qualify if:
- Patients with a diagnosis of any schizophrenia spectrum disorder after the diagnosis of bipolar disorder.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Related Publications (1)
Carlborg A, Thuresson M, Ferntoft L, Bodegard J. Characteristics of bipolar disorder patients treated with immediate- and extended-release quetiapine in a real clinical setting: a longitudinal, cohort study of 1761 patients. Ther Adv Psychopharmacol. 2015 Feb;5(1):13-21. doi: 10.1177/2045125314560740.
PMID: 25653826DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Andreas Carlborg, MD
Department of Clinical Neuroscience, Karolinska Institutet 171 76 Stockholm
Study Design
- Study Type
- observational
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 17, 2011
First Posted
October 20, 2011
Study Start
November 1, 2011
Primary Completion
April 1, 2012
Study Completion
April 1, 2012
Last Updated
August 21, 2014
Record last verified: 2014-08